Profile data is unavailable for this security.
About the company
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
- Revenue in EUR (TTM)843.74m
- Net income in EUR18.72m
- Incorporated--
- Employees1.79k
- LocationAlmirall SARonda General Mitre, 151BARCELONA 08022SpainESP
- Phone+34 932913000
- Fax+34 932913681
- Websitehttps://www.almirall.es/
More ▼
Mergers & acquisitions
| Acquired company | ALM:MCE since announced | Transaction value |
|---|---|---|
| DFT El Global SL-Physiorelax Portfolio | 0.22% | -- |
Data delayed at least 15 minutes, as of Feb 07 2023 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FAES Farma SA | 436.76m | 85.99m | 1.08bn | 1.66k | 12.62 | -- | 10.34 | 2.48 | 0.2766 | 0.2766 | 1.38 | -- | -- | -- | -- | 262,951.20 | -- | 12.75 | -- | 15.07 | 63.33 | 63.51 | 19.72 | 18.09 | -- | -- | -- | -- | 4.82 | 11.76 | 14.62 | 17.84 | 37.75 | 18.23 |
| Pharma Mar SA | 227.29m | 86.13m | 1.14bn | 477.00 | 12.99 | 5.28 | 12.44 | 5.01 | 4.77 | 4.52 | 12.58 | 11.75 | 0.6255 | 0.7861 | 8.24 | 476,496.80 | 23.70 | 16.04 | 31.01 | 24.70 | 94.46 | 91.18 | 37.89 | 20.58 | 2.72 | -- | 0.1612 | -- | -14.87 | 4.90 | -32.35 | -- | 5.07 | -- |
| Cosmo Pharmaceuticals NV | 78.15m | 35.28m | 1.17bn | 292.00 | 35.25 | 2.36 | 24.16 | 14.94 | 1.88 | 1.88 | 4.33 | 28.12 | 0.1177 | 2.92 | 3.81 | 268,444.20 | 5.32 | -2.09 | 5.51 | -2.16 | 53.43 | 59.64 | 45.17 | -19.05 | 10.81 | -- | 0.268 | -- | 6.77 | -0.7776 | 374.29 | 2.30 | -14.33 | -- |
| Eckert & Zieglr Strahln und Mdzntchnk AG | 213.44m | 28.61m | 1.19bn | 945.00 | 40.81 | 5.84 | 30.71 | 5.55 | 1.37 | 1.37 | 10.23 | 9.59 | 0.5951 | 2.44 | 6.11 | 246,463.00 | 8.11 | 8.38 | 9.60 | 10.13 | 49.67 | 47.84 | 13.62 | 12.77 | 2.34 | 53.28 | 0.1848 | 35.57 | 2.44 | 5.52 | 62.20 | 27.08 | 40.17 | 24.82 |
| Camurus AB | 76.38m | 2.50m | 1.20bn | 170.00 | 514.64 | 14.17 | 335.45 | 15.75 | 0.4815 | 0.4815 | 15.55 | 17.49 | 0.7643 | 0.9319 | 6.59 | 5,885,939.00 | 2.50 | -27.66 | 3.09 | -33.82 | 88.13 | 86.73 | 3.27 | -84.90 | 3.03 | 47.33 | 0.0253 | -- | 78.74 | 39.49 | 45.93 | -- | 1.59 | -- |
| Formycon AG | 38.98m | 76.73m | 1.21bn | 178.00 | 12.96 | 3.04 | 15.50 | 31.11 | 6.21 | 6.21 | 3.35 | 26.46 | 0.0871 | 61.10 | 2.47 | 227,935.70 | 17.17 | -6.59 | 17.81 | -7.39 | 31.97 | 29.53 | 197.04 | -8.86 | 2.12 | -- | 0.0456 | -- | 20.35 | 16.22 | -127.42 | -- | -2.05 | -- |
| AddLife AB | 796.47m | 42.09m | 1.31bn | 2.20k | 32.07 | 3.10 | 12.36 | 1.64 | 3.94 | 3.94 | 74.59 | 40.78 | 0.7681 | 3.99 | 6.57 | -- | 4.08 | 7.08 | 6.77 | 12.61 | 37.73 | 36.34 | 5.32 | 7.05 | 0.4322 | 3.94 | 0.5294 | 32.50 | 13.66 | 31.24 | -33.20 | 31.88 | 44.26 | 18.05 |
| Zealand Pharma A/S | 13.51m | -131.07m | 1.43bn | 203.00 | -- | 26.03 | -- | 105.87 | -22.13 | -25.89 | 2.27 | 7.91 | 0.0731 | 0.1002 | 1.76 | 283,371.80 | -70.93 | -27.88 | -88.11 | -32.49 | 94.20 | -- | -970.30 | -275.48 | 3.69 | -- | 0.575 | -- | -69.28 | -14.01 | 10.84 | -- | 53.47 | -- |
| Euroapi SAS | 943.90m | 2.00m | 1.46bn | 3.34k | 976.66 | 1.31 | 18.16 | 1.55 | 0.0159 | 0.0159 | 10.30 | 11.83 | -- | -- | -- | 282,435.70 | -- | -- | -- | -- | 16.44 | -- | 0.2225 | -- | 1.05 | 11.33 | 0.0363 | -- | -5.48 | -- | -150.79 | -- | -- | -- |
| Biotest AG | 505.00m | -70.89m | 1.51bn | 2.07k | -- | 2.46 | -- | 2.99 | -3.58 | -3.58 | 25.52 | 17.38 | 0.456 | 1.50 | 3.58 | 256,736.10 | -6.25 | -2.44 | -6.92 | -2.83 | 15.74 | 27.69 | -13.70 | -5.86 | 2.09 | -5.09 | 0.6138 | -- | 6.48 | 4.79 | -101.96 | -- | -32.84 | -- |
| Almirall SA | 843.74m | 18.72m | 1.68bn | 1.79k | 89.85 | 1.23 | 39.54 | 1.99 | 0.1028 | 0.1028 | 4.60 | 7.52 | 0.372 | 1.46 | 6.30 | 472,417.10 | 0.8255 | -0.7384 | 0.9264 | -0.8645 | 78.18 | 77.53 | 2.22 | -2.24 | 1.71 | 5.61 | 0.2104 | -- | 2.45 | 1.59 | -155.01 | -- | -2.82 | -- |
| BioArctic AB | 20.02m | -980.24k | 1.98bn | 56.00 | -- | 34.30 | 6,525.76 | 98.73 | -0.14 | -0.14 | 2.59 | 8.92 | 0.26 | -- | -- | -- | -1.27 | 4.90 | -1.41 | 5.96 | 85.54 | 88.98 | -4.90 | 20.66 | -- | -- | 0.0126 | 40.83 | 886.31 | 10.16 | 90.67 | -- | -- | -- |
| Dermapharm Holding SE | 1.01bn | 175.99m | 2.09bn | 2.57k | 11.86 | 4.15 | 8.05 | 2.08 | 3.28 | 3.28 | 18.74 | 9.36 | 0.7214 | 1.40 | 10.62 | 424,346.80 | 12.53 | 12.37 | 14.49 | 14.46 | 64.41 | 57.21 | 17.37 | 15.12 | 1.26 | 41.22 | 0.5435 | -- | 18.78 | 16.23 | 144.20 | 65.61 | 28.08 | -- |
| Genus plc | 664.56m | 45.80m | 2.12bn | 3.33k | 46.23 | 3.28 | 25.04 | 3.19 | 0.6235 | 0.6235 | 9.04 | 8.80 | 0.635 | -- | 5.04 | 178,466.20 | 3.93 | 3.23 | 4.64 | 3.80 | -- | -- | 6.18 | 5.04 | 1.37 | 113.60 | 0.2812 | 67.18 | 3.33 | 5.27 | -13.53 | 4.51 | 28.18 | 6.28 |
| Laboratorios Farmaceuticos ROVI SA | 760.67m | 175.64m | 2.15bn | 1.85k | 11.89 | 4.63 | 11.08 | 2.83 | 3.36 | 3.36 | 14.40 | 8.61 | 1.04 | 1.16 | 5.86 | 434,422.00 | 24.10 | 12.56 | 33.83 | 16.27 | 60.76 | 58.31 | 23.09 | 14.22 | 0.9743 | 123.81 | 0.1424 | 33.04 | 54.46 | 19.59 | 150.71 | 42.46 | 17.76 | 39.18 |
| Bavarian Nordic A/S | 322.85m | -80.47m | 2.19bn | 917.00 | -- | 2.34 | -- | 6.79 | -8.68 | -8.68 | 36.30 | 98.47 | 0.2146 | 2.61 | 4.96 | 3,167,704.00 | -5.35 | -2.42 | -6.74 | -2.93 | 37.85 | 45.79 | -24.92 | -11.37 | 1.71 | -1.64 | 0.3719 | -- | 2.46 | 13.52 | -267.47 | -- | 63.17 | -- |
Data as of Feb 07 2023. Currency figures normalised to Almirall SA's reporting currency: Euro EUR
12.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 17 Nov 2021 | 9.08m | 5.00% |
| Caixabank Asset Management SGIIC SAas of 30 Sep 2022 | 3.34m | 1.84% |
| The Vanguard Group, Inc.as of 05 Jan 2023 | 2.01m | 1.11% |
| Artisan Partners LPas of 30 Jun 2022 | 2.00m | 1.10% |
| Degroof Petercam Asset Management SAas of 30 Sep 2022 | 1.41m | 0.78% |
| Wellington Management International Ltd.as of 30 Dec 2022 | 1.30m | 0.72% |
| Bessemer Investment Management LLCas of 31 Oct 2022 | 1.25m | 0.69% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 1.20m | 0.66% |
| Dimensional Fund Advisors LPas of 05 Jan 2023 | 975.01k | 0.54% |
| BlackRock Fund Advisorsas of 05 Jan 2023 | 935.66k | 0.52% |
More ▼
Data from 31 Dec 2021 - 30 Dec 2022Source: FactSet Research Systems Inc.
